Last reviewed · How we verify
Conventional antithrombotic strategy — Competitive Intelligence Brief
marketed
Antithrombotic agents (antiplatelet and/or anticoagulant)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Conventional antithrombotic strategy (Conventional antithrombotic strategy) — Duk-Woo Park, MD. Conventional antithrombotic strategy prevents blood clot formation through antiplatelet and/or anticoagulant agents to reduce thrombotic events.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Conventional antithrombotic strategy TARGET | Conventional antithrombotic strategy | Duk-Woo Park, MD | marketed | Antithrombotic agents (antiplatelet and/or anticoagulant) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antithrombotic agents (antiplatelet and/or anticoagulant) class)
- Duk-Woo Park, MD · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Conventional antithrombotic strategy CI watch — RSS
- Conventional antithrombotic strategy CI watch — Atom
- Conventional antithrombotic strategy CI watch — JSON
- Conventional antithrombotic strategy alone — RSS
- Whole Antithrombotic agents (antiplatelet and/or anticoagulant) class — RSS
Cite this brief
Drug Landscape (2026). Conventional antithrombotic strategy — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-antithrombotic-strategy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing